Your browser doesn't support javascript.
loading
Translating meningococcal serogroup B vaccines for healthcare professionals.
Safadi, Marco Aurelio P; Martinón-Torres, Federico; Serra, Lidia; Burman, Cynthia; Presa, Jessica.
Afiliación
  • Safadi MAP; Department of Pediatrics, Santa Casa De São Paulo School of Medical Sciences, São Paulo, Brazil.
  • Martinón-Torres F; Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario De Santiago De Compostela, Santiago De Compostela, Spain.
  • Serra L; Genetics, Vaccines and Pediatrics Research Group, Universitario De Santiago De Compostela, Instituto De Investigación Sanitaria De Santiago De Compostela, Santiago De Compostela, Spain.
  • Burman C; Pfizer Vaccine Medical Development, Scientific and Clinical Affairs, Collegeville, PA, USA.
  • Presa J; Pfizer Vaccine Medical Development, Scientific and Clinical Affairs, Collegeville, PA, USA.
Expert Rev Vaccines ; 20(4): 401-414, 2021 04.
Article en En | MEDLINE | ID: mdl-34151699
INTRODUCTION: Vaccination is an effective strategy to combat invasive meningococcal disease (IMD). Vaccines against the major disease-causing meningococcal serogroups are available; however, development of vaccines against serogroup B faced particular challenges, including the inability to target traditional meningococcal antigens (i.e. polysaccharide capsule) and limited alternative antigens due to serogroup B strain diversity. Two different recombinant, protein-based, serogroup B (MenB) vaccines that may address these challenges are currently available. These vaccines have been extensively evaluated in pre-licensure safety and immunogenicity trials, and recently in real-world studies on effectiveness, safety, and impact on disease burden. AREAS COVERED: This review provides healthcare professionals, particularly pediatricians, an overview of currently available MenB vaccines, including development strategies and evaluation of coverage. EXPERT OPINION: Overall, recombinant MenB vaccines are valuable tools for healthcare professionals to protect patients against IMD. Their development required innovative design approaches that overcame challenging hurdles and identified novel protein antigen targets; however, important distinctions in the approaches used in their development, evaluation, and administration exist and many unanswered questions remain. Healthcare providers frequently prescribing MenB vaccines are challenged to keep abreast of these differences to ensure patient protection against this serious disease.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Meningococicas / Neisseria meningitidis Serogrupo B / Infecciones Meningocócicas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Expert Rev Vaccines Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas Meningococicas / Neisseria meningitidis Serogrupo B / Infecciones Meningocócicas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Expert Rev Vaccines Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Brasil Pais de publicación: Reino Unido